

# European Respiratory Society Annual Congress 2012

**Abstract Number:** 453

**Publication Number:** P3459

**Abstract Group:** 1.12. Clinical Problems - COPD

**Keyword 1:** COPD - management **Keyword 2:** Treatments **Keyword 3:** Bronchodilators

**Title:** Effect of fluticasone propionate/salmeterol on exercise endurance in moderate-severe COPD

Dr. Wenlan 746 Yang yangwenlan888@hotmail.com <sup>1</sup>, Prof. Dr Jinming 747 Liu jinmingliu\_sh@hotmail.com MD <sup>2</sup>, Dr. Beilan 748 Gao gaobeilan66@hotmail.com <sup>2</sup> and Dr. Keping 749 Cheng kb.c@163.com <sup>2</sup>. <sup>1</sup> Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China, 200433 and <sup>2</sup> Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China, 200433 .

**Body:** Objective To investigate the effect of Fluticasone Propionate/Salmeterol on exercise endurance and pulmonary function in patients with moderate-severe COPD. Methods 53 patients with moderate-severe COPD were randomly divided to two groups. Treatment group inhaled dry powder SFC(salmeterol 50ug, fluticasone Propionate 250ug) twice daily for 24 weeks. Control group got symptomatic treatment for 24 weeks. Predose and postdose pulmonary and cycle cardiopulmonary exercise test evaluations were compared. Results There were no difference in predose pulmonary and CPET between two groups. In treatment group, With SFC treatment for 24weeks, FVC, FEV<sub>1</sub>, IC were significant increased; ITGV,RV and TLV were significant decreased(p<0.05); Peak WR increased, but had no statisticly difference. Peak VO<sub>2</sub>, peak VO<sub>2</sub>/Kg, peak VCO<sub>2</sub>, peak O<sub>2</sub> pulse, peak VE were significant increased(p<0.05); VD/VT and lowest VE/VCO<sub>2</sub> were decreased from (p<0.05); postdose improvement in IC was significantly correlated with the increase in Peak VO<sub>2</sub>, Peak VO<sub>2</sub>/Kg, Peak VE, VD/VT and Lowest VE/VCO<sub>2</sub>,but not with FEV<sub>1</sub>. Predose and postdose pulmonary and CPET were no changes in control group. Conclusion Exercise tolerance in patients with moderate-severe COPD were distinguished impaired. After long term SFC treatment, lung hyperinflation at rest and exercise were decreased, exercise endurance were increased when compared with symptomatic treatment. CPET is useful in COPD patients as it allows objective measurement of the exercise tolerance and evaluation of the response to therapeutic intervention.